Anterogen.Co.Ltd (A065660) Stock Overview
A bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A065660 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Anterogen.Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩44,100.00 |
| 52 Week High | ₩61,800.00 |
| 52 Week Low | ₩18,600.00 |
| Beta | 0.25 |
| 1 Month Change | 21.32% |
| 3 Month Change | 9.98% |
| 1 Year Change | 125.46% |
| 3 Year Change | 117.78% |
| 5 Year Change | -10.27% |
| Change since IPO | 12.79% |
Recent News & Updates
Recent updates
We're Hopeful That Anterogen.Co.Ltd (KOSDAQ:065660) Will Use Its Cash Wisely
Dec 01
Does Anterogen.Co.Ltd (KOSDAQ:065660) Have A Healthy Balance Sheet?
Apr 04Health Check: How Prudently Does Anterogen.Co.Ltd (KOSDAQ:065660) Use Debt?
Feb 05Does Anterogen.Co.Ltd's (KOSDAQ:065660) Share Price Gain of 25% Match Its Business Performance?
Dec 14
Shareholder Returns
| A065660 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -23.4% | -7.1% | -2.7% |
| 1Y | 125.5% | 27.3% | 99.2% |
Return vs Industry: A065660 exceeded the KR Biotechs industry which returned 37.4% over the past year.
Return vs Market: A065660 exceeded the KR Market which returned 112.2% over the past year.
Price Volatility
| A065660 volatility | |
|---|---|
| A065660 Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in KR Market | 15.6% |
| 10% least volatile stocks in KR Market | 4.4% |
Stable Share Price: A065660's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A065660's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Seong-Gu Lee | anterogen.com |
Anterogen Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension.
Anterogen.Co.,Ltd. Fundamentals Summary
| A065660 fundamental statistics | |
|---|---|
| Market cap | ₩441.27b |
| Earnings (TTM) | -₩1.37b |
| Revenue (TTM) | ₩7.54b |
Is A065660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A065660 income statement (TTM) | |
|---|---|
| Revenue | ₩7.54b |
| Cost of Revenue | ₩4.88b |
| Gross Profit | ₩2.66b |
| Other Expenses | ₩4.03b |
| Earnings | -₩1.37b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -137.30 |
| Gross Margin | 35.25% |
| Net Profit Margin | -18.23% |
| Debt/Equity Ratio | 0% |
How did A065660 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/23 04:26 |
| End of Day Share Price | 2026/03/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anterogen.Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.